Show simple item record

dc.creatorVeljković, Veljko
dc.creatorMuller, S
dc.creatorKohler, Heike
dc.date.accessioned2018-03-01T19:19:06Z
dc.date.available2018-03-01T19:19:06Z
dc.date.issued2003
dc.identifier.issn0264-410X (print)
dc.identifier.urihttp://vinar.vin.bg.ac.rs/handle/123456789/2665
dc.description.abstractResearch and clinical data reported during last 10 years indicate the possibility that AIDS vaccines based on the HIV-1 envelope protein gp120 may be worse then useless. A correct assessment of the safety of these AIDS vaccines can not be possible without data which will allow comparison of the disease status between breakthrough HIV infected vaccinated volunteers and those from the control group. Results of the recently finished clinical trial of AIDSVAX represent a good base for this important analysis. (C) 2003 Elsevier Science Ltd. All rights reserved.en
dc.rightsrestrictedAccessen
dc.sourceVaccineen
dc.subjectAIDSVAXen
dc.subjectpopulation explosionen
dc.subjectAIDSen
dc.titleAIDSVAX results: an important open questionen
dc.typearticleen
dcterms.abstractМуллер, С; Кохлер, Х; Вељковић Вељко;
dc.citation.volume21
dc.citation.issue25-26
dc.citation.spage3528
dc.citation.epage3529
dc.identifier.wos000185233700004
dc.identifier.doi10.1016/S0264-410X(03)00324-4
dc.citation.rankM21a
dc.identifier.pmid12922078
dc.identifier.scopus2-s2.0-0242349141


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record